Nektar Therapeutics

Key facts

Headquarters

San Francisco, California, United States

Employees

61

Industries

Biotechnology, Health Care

Status

Public (NKTR)

Website

www.nektar.com

LinkedIn

Company page

Recent activity at Nektar Therapeutics

• Oct 01, 2026: SEC 8-K (7.01): On October 1, 2026, Nektar Therapeutics issued a press release detailing new data from its Phase 2b REZOLVE-AA clinical trial focused on alopecia areata. The company also provided a presentation containing additional information about the trial, which is accessible on its investor relations website. This disclosure is intended to comply with Regulation FD, ensuring that all investors have equal access to important information. The press release and presentation do not constitute a 'filed' document per the Securities Exchange Act but are furnished for informational purposes. The strategic implications of this trial data could impact future investment and growth for the company as it progresses in its clinical trials.
• Sep 25, 2026: SEC 8-K (8.01): On September 24, 2026, a jury found Eli Lilly and Company liable for breaching the implied covenant of good faith and fair dealing in connection with a License Agreement with Nektar Therapeutics. Nektar Therapeutics filed the case, Nektar Therapeutics v. Eli Lilly & Co., arising from their collaboration on the development of rezpegaldesleukin. The jury awarded Nektar $90 million in damages, plus interest, pending further post-trial proceedings and potential appeals. This verdict significantly impacts Nektar's financial position and legal standing in the pharmaceutical market.
• Sep 08, 2026: SEC 8-K (7.01): Nektar Therapeutics has announced the initiation of a quiet period starting September 8, 2026, as part of its preparation for the public announcement of data from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study, which focuses on the drug rezpegaldesleukin for patients suffering from severe-to-very-severe alopecia areata. This period is consistent with the Company’s previous quiet periods related to the REZOLVE studies and planned data disclosures. The quiet period aims to uphold the integrity of the data release, which is critical for investor relations and compliance with regulatory requirements.
• May 08, 2026: SEC 8-K (5.02): On May 7, 2026, the Company announced the retirement of Sandra Gardiner as the interim Chief Financial Officer, effective May 15, 2026. Linda Rubinstein will succeed her in this role. Rubinstein, a highly experienced financial professional with a history of leading roles in various companies, including her recent position at Adverum Biotechnologies, Inc., will be compensated under an amended consulting agreement with FLG Partners, LLC, at a rate of $650 per hour. The agreement includes terms for indemnification and can be terminated with 15 days' notice, reflecting a significant transition in the Company’s financial leadership just days before the effective date of the change.
• Apr 23, 2026: SEC 8-K (1.01): On April 21, 2026, Nektar Therapeutics entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. for an underwritten offering of 3,532,609 shares of common stock at a public price of $92.00 per share, expected to close on April 23, 2026. The Company also granted a 30-day option for underwriters to purchase an additional 529,891 shares, which they exercised in full on April 22, 2026, bringing the expected net proceeds to approximately $350.9 million after expenses. This agreement includes customary covenants and indemnification obligations, with details provided in the full underwriting agreement filed as an exhibit. The offering is conducted under an effective shelf registration statement previously filed with the SEC.
• Apr 20, 2026: SEC 8-K (7.01): On April 20, 2026, Nektar Therapeutics announced that it had approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This announcement, categorized under Regulation FD, provides insights into the company's financial position, although it is not a comprehensive statement of its operating results. The figures reported were generated from information available to the company at the time of the announcement and do not reflect a formal filing. This disclosure is significant as it indicates the company's liquidity status and its financial health leading up to this date, but the company clarifies that the information should not be construed as officially 'filed' for certain legal purposes.
• Apr 20, 2026: SEC 8-K (8.01): On April 20, 2026, the Company reported the 52-week topline results from the blinded 16-week treatment extension period of its REZOLVE-AA study involving 92 patients with severe-to-very-severe alopecia areata. The extension followed a 36-week induction phase, and results showed that patients taking rezpegaldesleukin achieved significant improvements in SALT Scores, with 25.8% and 27.6% of patients in the low and high dose groups achieving a SALT Score ≤20, respectively, by week 52. Importantly, the study's statistical significance was supported by p-values of 0.049 and 0.023 for different measures, indicating that the treatment was effective compared to placebo. The Company intends to present these results at a medical conference in 2026, which may impact future research and treatment strategies for alopecia areata.
• Feb 13, 2026: SEC 8-K (1.01): On February 11, 2026, Nektar Therapeutics entered into a material definitive underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. for an underwritten offering of 6,603,449 shares of its common stock at a public price of $58.00 per share and pre-funded warrants for 293,103 shares at $57.9999 each. The underwriters, who were granted a 30-day option to purchase an additional 1,034,482 shares, exercised this option in full on February 12, 2026. The offering is expected to close on February 13, 2026, and the company anticipates net proceeds of approximately $432.0 million after costs. This transaction is significant as it aids in raising capital for further corporate activities, reflecting strategic movements in the market.
• Feb 10, 2026: SEC 8-K (8.01): On February 10, 2026, the Company announced results from the 36-week blinded maintenance period of its Phase 2b REZOLVE-AD study focusing on the treatment of moderate-to-severe atopic dermatitis with rezpegaldesleukin. In this global study involving 393 patients, significant efficacy was observed, with re-randomized patients achieving enhanced response rates in disease control metrics such as EASI-100 and validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD). The 24 µg/kg dosages administered either monthly or quarterly showed a marked improvement in maintaining response rates over the maintenance period, suggesting prolonged therapy may lead to better disease management. This event highlights important advancements in therapeutic strategies for atopic dermatitis, with implications for patient care and treatment protocols.
• Feb 10, 2026: SEC 8-K (7.01): On February 10, 2026, Nektar Therapeutics announced its cash and investments in marketable securities totaled approximately $229.1 million as of January 31, 2026. This disclosure reflects the company's financial position and operating estimates up to the announcement date. The report clarifies that the amounts are not intended to be a comprehensive statement of financial results as of January 31, 2026. The strategic implications of this announcement underscore the company's liquidity position, providing insight into its financial health prior to upcoming operational decisions.

Nektar Therapeutics funding history

Leadership

• Nalinikanth Pathi, Director - IT, PMP, CSM
• Mary Tagliaferri, Senior Vice President, Chief Medical Officer
• Ramesh Panchagnula, Independent Consultant
• Jennifer Ruddock, SVP & Chief Business Officer
• Elizabeth Zhang, Chief Legal Officer
• Robert Bacci, Chief People Officer

Verified email and direct lines for Nektar Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Nektar Therapeutics files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Nektar Therapeutics in the news

• Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire (Oct 23, 2026)
• Nektar Therapeutics Announces Second Quarter 2026 Financial Results - PR Newswire (Aug 13, 2026)
• Nektar Therapeutics Reports First Quarter 2026 Financial Results - PR Newswire (May 07, 2026)
• Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PR Newswire (Jul 21, 2026)
• Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis - PR Newswire (Feb 17, 2026)
• Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire (Apr 23, 2026)
• Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan - PR Newswire (Apr 17, 2023)
• Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus - PR Newswire (Feb 23, 2023)

Companies similar to Nektar Therapeutics

• SCYNEXIS · Biotechnology, Health Care
• Scene Health · Biotechnology, Health Care
• ZeroHarm Sciences · Biotechnology, Health Care
• Syapse Holdings · Biotechnology, Health Care
• New Horizon Medical Solutions · Biotechnology, Health Care

About Nektar Therapeutics: questions and answers

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy